“Trametinib’s Effectiveness in Attenuating Cancer Stem Cell Activity in Anaplastic Thyroid Cancer: Implications for Treatment and Relapse”

https://pubmed.ncbi.nlm.nih.gov/38115586

The MEK inhibitor trametinib effectively attenuates cancer stem cell activity in anaplastic thyroid cancer, contributing to the efficacy of the combined BRAF and MEK inhibitor treatment, but some CSC activity remains, which may explain the recurrence observed in patients.